Vimizim IV infusion 5mg, containing Elosulfase alpha (genetically recombined), is manufactured by BioMarin Pharmaceutical Japan. This injectable drug, with YJ code 3959417A1027 and standard 5mg x 5mL x 1 bottle, is an enzyme replacement therapy for Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).
Vimizim IV infusion 5mg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →